{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:20:41Z","timestamp":1780647641000,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T00:00:00Z","timestamp":1493337600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T00:00:00Z","timestamp":1493337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wellstat Immunotherapeutics Corp","award":["CRADA C-087-2006 (2006-0203)"],"award-info":[{"award-number":["CRADA C-087-2006 (2006-0203)"]}]},{"name":"Wellstat Diagnostics, LLC","award":["CRADA C-022-2006 (2006-0369)"],"award-info":[{"award-number":["CRADA C-022-2006 (2006-0369)"]}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004756","name":"Emil Aaltosen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00125-017-4276-5","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T07:45:34Z","timestamp":1493365534000},"page":"1475-1482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Metabolically inactive insulin analogue does not prevent autoimmune diabetes in NOD mice"],"prefix":"10.1007","volume":"60","author":[{"given":"Juha","family":"Gr\u00f6nholm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe P.","family":"Pagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh N.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire B.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Macomber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Vela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"von Herrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Lenardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,28]]},"reference":[{"key":"4276_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","volume":"383","author":"MA Atkinson","year":"2014","unstructured":"Atkinson MA, Eisenbarth GS, Michels AW (2014) Type 1 diabetes. Lancet 383:69\u201382","journal-title":"Lancet"},{"key":"4276_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1146\/annurev.immunol.23.021704.115643","volume":"23","author":"MS Anderson","year":"2005","unstructured":"Anderson MS, Bluestone JA (2005) The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 23:447\u2013485","journal-title":"Annu Rev Immunol"},{"key":"4276_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1146\/annurev-immunol-032712-095941","volume":"32","author":"ER Unanue","year":"2014","unstructured":"Unanue ER (2014) Antigen presentation in the autoimmune diabetes of the NOD mouse. Annu Rev Immunol 32:579\u2013608","journal-title":"Annu Rev Immunol"},{"key":"4276_CR4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nrendo.2014.236","volume":"11","author":"JC Reed","year":"2015","unstructured":"Reed JC, Herold KC (2015) Thinking bedside at the bench: the NOD mouse model of T1DM. Nat Rev Endocrinol 11:308\u2013314","journal-title":"Nat Rev Endocrinol"},{"key":"4276_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nature03523","volume":"435","author":"M Nakayama","year":"2005","unstructured":"Nakayama M, Abiru N, Moriyama H et al (2005) Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435:220\u2013223","journal-title":"Nature"},{"key":"4276_CR6","doi-asserted-by":"publisher","first-page":"8384","DOI":"10.1073\/pnas.0932778100","volume":"100","author":"SM Lieberman","year":"2003","unstructured":"Lieberman SM, Evans AM, Han B et al (2003) Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci U S A 100:8384\u20138388","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4276_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.clim.2014.11.007","volume":"156","author":"J Gr\u00f6nholm","year":"2015","unstructured":"Gr\u00f6nholm J, Lenardo MJ (2015) Novel diagnostic and therapeutic approaches for autoimmune diabetes\u2014a prime time to treat insulitis as a disease. Clin Immunol 156:109\u2013118","journal-title":"Clin Immunol"},{"key":"4276_CR8","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1073\/pnas.040556697","volume":"97","author":"L Yu","year":"2000","unstructured":"Yu L, Robles DT, Abiru N et al (2000) Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A 97:1701\u20131706","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4276_CR9","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2337\/diab.39.8.933","volume":"39","author":"MA Atkinson","year":"1990","unstructured":"Atkinson MA, Maclaren NK, Luchetta R (1990) Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39:933\u2013937","journal-title":"Diabetes"},{"key":"4276_CR10","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1172\/JCI117707","volume":"95","author":"A Muir","year":"1995","unstructured":"Muir A, Peck A, Clare-Salzler M et al (1995) Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J Clin Invest 95:628\u2013634","journal-title":"J Clin Invest"},{"key":"4276_CR11","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1172\/JCI119654","volume":"100","author":"DG Karounos","year":"1997","unstructured":"Karounos DG, Bryson JS, Cohen DA (1997) Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice. J Clin Invest 100:1344\u20131348","journal-title":"J Clin Invest"},{"key":"4276_CR12","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1084\/jem.20110574","volume":"208","author":"C Daniel","year":"2011","unstructured":"Daniel C, Weigmann B, Bronson R, von Boehmer H (2011) Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope. J Exp Med 208:1501\u20131510","journal-title":"J Exp Med"},{"key":"4276_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/BF03347752","volume":"17","author":"JZ Zhang","year":"1994","unstructured":"Zhang JZ, Davidson L, Eisenbarth G et al (1994) Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. J Endocrinol Investig 17:573\u2013580","journal-title":"J Endocrinol Investig"},{"key":"4276_CR14","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1084\/jem.184.6.2167","volume":"184","author":"LC Harrison","year":"1996","unstructured":"Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K (1996) Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 184:2167\u20132174","journal-title":"J Exp Med"},{"key":"4276_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.clim.2016.01.013","volume":"164","author":"MN Pham","year":"2016","unstructured":"Pham MN, Gibson C, Ryd\u00e9n AKE et al (2016) Oral insulin (human, murine, or porcine) does not prevent diabetes in the non-obese diabetic mouse. Clin Immunol 164:28\u201333","journal-title":"Clin Immunol"},{"key":"4276_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1600-065X.2010.00917.x","volume":"236","author":"AL Snow","year":"2010","unstructured":"Snow AL, Pnadiyan P, Zheng L et al (2010) The power and the promise of restimulation-induced cell death in human immune diseases. Immunol Rev 236:68\u201382","journal-title":"Immunol Rev"},{"key":"4276_CR17","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1126\/science.7509084","volume":"263","author":"JM Critchfield","year":"1994","unstructured":"Critchfield JM, Racke MK, Zuniga-Pflucker JC et al (1994) T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263:1139\u20131143","journal-title":"Science"},{"key":"4276_CR18","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.4049\/jimmunol.166.3.2116","volume":"166","author":"HI Mcfarland","year":"2001","unstructured":"Mcfarland HI, Lobito AA, Johnson MM et al (2001) Effective antigen-specific immunotherapy in the marmoset model of multiple sclerosis. J Immunol 166:2116\u20132121","journal-title":"J Immunol"},{"key":"4276_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(00)02579-4","volume":"356","author":"L Chaillous","year":"2000","unstructured":"Chaillous L, Lef\u00e8vre H, Thivolet C et al (2000) Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Lancet 356:545\u2013549","journal-title":"Lancet"},{"key":"4276_CR20","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa012350","volume":"346","author":"Diabetes Prevention Trial\u2014Type 1 Diabetes Study Group","year":"2002","unstructured":"Diabetes Prevention Trial\u2014Type 1 Diabetes Study Group (2002) Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346:1685\u20131691","journal-title":"N Engl J Med"},{"key":"4276_CR21","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/j.1464-5491.1991.tb02122.x","volume":"8","author":"A V\u00f8lund","year":"1991","unstructured":"V\u00f8lund A, Brange J, Drejer K et al (1991) In vitro and in vivo potency of insulin analogues designed for clinical use. Diabet Med 8:839\u2013847","journal-title":"Diabet Med"},{"key":"4276_CR22","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.4049\/jimmunol.163.4.1833","volume":"163","author":"D Homann","year":"1999","unstructured":"Homann D, Dyrberg T, Petersen J et al (1999) Insulin in oral immune \u201ctolerance\u201d: a one-amino acid change in the B chain makes the difference. J Immunol 163:1833\u20131838","journal-title":"J Immunol"},{"key":"4276_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20022125","volume":"198","author":"MJI Ansari","year":"2003","unstructured":"Ansari MJI, Salama AD, Chitnis T et al (2003) The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198:63\u201369","journal-title":"J Exp Med"},{"key":"4276_CR24","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.4049\/jimmunol.178.10.6051","volume":"178","author":"MG Levisetti","year":"2007","unstructured":"Levisetti MG, Suri A, Petzold SJ, Unanue ER (2007) The insulin-specific T cells of nonobese diabetic mice recognize a weak MHC-binding segment in more than one form. J Immunol 178:6051\u20136057","journal-title":"J Immunol"},{"key":"4276_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/1479-5876-9-203","volume":"9","author":"B Lo","year":"2011","unstructured":"Lo B, Swafford ADE, Shafer-Weaver KA et al (2011) Antibodies against insulin measured by electrochemiluminescence predicts insulitis severity and disease onset in non-obese diabetic mice and can distinguish human type 1 diabetes status. J Transl Med 9:203","journal-title":"J Transl Med"},{"key":"4276_CR26","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.2337\/db15-0492","volume":"65","author":"RG Gill","year":"2015","unstructured":"Gill RG, Pagni PP, Kufper T et al (2015) A preclinical consortium approach for assessing the efficacy of combined anti-CD3 plus IL-1 blockade in reversing new-onset autoimmune diabetes in NOD mice. Diabetes 65:1310\u20131316","journal-title":"Diabetes"},{"key":"4276_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/ni.1850","volume":"11","author":"JF Mohan","year":"2010","unstructured":"Mohan JF, Levisetti MG, Calderon B et al (2010) Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nat Immunol 11:350\u2013354","journal-title":"Nat Immunol"},{"key":"4276_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.immuni.2005.08.002","volume":"2","author":"LD Shoda","year":"2005","unstructured":"Shoda LD, Young DL, Ramanujan S et al (2005) A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2:115\u2013126","journal-title":"Immunity"},{"key":"4276_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1055\/s-2007-978622","volume":"6","author":"R Liddi","year":"2000","unstructured":"Liddi R, Beales PE, Rosignoli G, Pozzilli P (2000) Incomplete Freund\u2019s adjuvant reduces diabetes in the non-obese diabetic mouse. Horm Metab Res 6:201\u2013206","journal-title":"Horm Metab Res"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-017-4276-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-017-4276-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-017-4276-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T09:45:25Z","timestamp":1692783925000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-017-4276-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,28]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["4276"],"URL":"https:\/\/doi.org\/10.1007\/s00125-017-4276-5","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,28]]},"assertion":[{"value":"4 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The datasets generated during and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This research was supported by the Division of Intramural Research, NIAID, Clinical Center and National Human Genome Research Institute, NIH. JG was supported by a fellowship grant from the Sigrid Juselius Foundation and by a grant from the Emil Aaltonen Foundation. Wellstat Immunotherapeutics supported this research with Cooperative Research and Development Agreement (CRADA) C-087-2006 (2006-0203) and Wellstat Diagnostics with CRADA C-022-2006 (2006-0369)<b>.<\/b> The study was also funded in part by Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MvH, JLV, PPP, CBG and MNP are employed or affiliated with Novo Nordisk. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}},{"value":"JG, MvH, JLV, PPP and MJL designed the experiments. JG, JLV, PPP, MNP, PFM and CBG performed the experiments and analysed the results. JG, PPP, MNP, PFM and JLV drafted the manuscript. All authors performed critical analysis of the manuscript and approved the final version to be published. MJL is a guarantor of this study and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}